FOXO3: the longevity gene that shapes lifespan
Forbes - 04-Jan-2024Scientists explore how this key gene affects aging—and how lifestyle may activate its benefits
FOXO Technologies
Modernizing the longevity insurance industry with molecular biotechnology
FOXO Technologies is transforming the global longevity insurance industry with a next-generation underwriting protocol and consumer engagement platform based on epigenetic technology and insights.FOXO Technologies Inc. uses AI-driven bioinformatics and microarray technologies to develop and commercialize epigenetic biomarkers of health and aging.
FOXO provides insurers, health researchers, and life science companies with laboratory services, microarray design, and AI-driven bioinformatics software solutions for generating novel health-based insights into lifespan.
Visit website: https://foxotechnologies.com/
Details last updated 24-Apr-2021
FOXO Technologies News
FOXO licenses use of epigenetic clocks in life insurance industry
Longevity Technology - 05-May-2021Modernizing life insurance to keep its customers healthy and alive
FOXO Technologies is also referenced in the following:
ARDD 2021 - 8th Aging Research and Drug Discovery Meeting
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
People at FOXO Technologies
Topics mentioned on this page:
Epigenetics
